...[C.] Samuel is leading Gilead's global access program, an innovative tiered pricing scheme that sells drugs at full price in developed countries, 70 percent to 90 percent less in middle-income countries like Brazil, and at no profit in the poorest nations. So, life-saving HIV drugs cost $100,000 to $200,000 a year in 130 of the world's poorest countries...[G.Alton, Gilead:] "We don't give the product away for free in any market. So, our program is not a philanthropy, it's a sustainable program...We make the product available at our cost"...Gilead has also begun to license its formulas to Indian generic drug firms...[also refers to Viiv, a Pfizer and GlaxoSmithKline joint venture]